Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD

Margaux M. Salas, PhD · NCT06414356

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–70 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
30
US sites recruiting
1
Study start
October 2, 2024
Record last updated
February 25, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is aimed to evaluate outpatient ketamine infusion within a military chronic neuropathic pain population and its effect on PTSD. Currently, this is a pilot study with 30 participants. Participants will be randomized to (1) a moderate dose ketamine, (2) moderate dose ketamine +Mg, or (3) a magnesium control group. Participants will complete self-reported pain and PTSD questionnaires throughout the \~24-week study period. The outlined strategy will provide evidence for the utility of ketamine in neuropathic pain management and pain associated comorbidities within a military population.

Being studied: Ketamine; Magnesium sulfate; Ketamine + Magnesium sulfate

Conditions: Neuropathic Pain; PTSD

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • 18-70 years old with Chronic Neuropathic Pain >= 3 months
  • Biologic male or biologic female
  • Women of childbearing age will be included if there are no plans of pregnancy within the study period, the participant agrees to actively utilize contraception throughout the study, and agrees to pregnancy tests
  • Active Duty, Veterans, and retirees
  • Ketamine naïve for 1 year
  • Moderate Neuropathic pain Scale 4-7

Exclusion Criteria

  • Cognitive dysfunction
  • Psychiatric illness involving psychosis
  • Neurocognitive disorder
  • Patients with Traumatic Brain Injury (TBI)
  • Acute cardiovascular disease or poorly controlled hypertension
  • Untreated or uncontrolled thyroid disease
  • Hyperthyroidism
  • Severe liver or renal disease
  • Renal impairment
  • History of recent heart attack, vascular disease, or any other medical condition that may be deemed by a provider as a contraindication to receiving ketamine
  • Active substance abuse
  • Pregnant or lactating
  • Patients who are planning to become pregnant within 12 weeks of treatment completion
  • Elevated Blood Pressure/hypertension
  • Known hypersensitivity to Ketamine
  • Hemodynamic instability
  • Respiratory depression
  • Use of Theophylline or Aminophylline, Sympathomimetics and Vasopressin,
  • Use of Benzodiazepines
  • A history of drug abuse or dependence
  • Active risk of substance use
  • Patients who are not able to abide by the pre-treatment and posttreatment clinical protocol, such as food intake, abstaining from certain medications, unable to remain in the clinic for a minimum of 1 hour for observation, and cannot provide the name and phone number of the party who will pick them up post-treatment

Recruiting US locations

  • Brooke Army Medical Center

    San Antonio, TX 78234

    Site contact: Kevin Peterson, MD · 210-916-2888 · kevin.c.peterson3.mil@health.mil

Study contacts (from the official record)

  • Margaux M Salas, PhD · 210-473-7447 · margaux.m.salas.ctr@health.mil
  • Kevin C Peterson, MD · 210-916-7331 · kevin.c.peterson3.mil@health.mil
The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic… (NCT06414356) | Bored Studies